Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.

Literature DB >> 28039369

Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.

Patrick Roth¹, Antonios Valavanis², Michael Weller³.

Abstract

Entities: Chemical Disease

Keywords: PD-1zzm321990pseudoprogression; glioblastoma; iRANO; nivolumab

Mesh：

Substances：

Year: 2017 PMID： 28039369 PMCID： PMC5464329 DOI： 10.1093/neuonc/now265

Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300

× No keyword cloud information.

3 in total

Review 1. Immunotherapy for glioblastoma: concepts and challenges.

Authors: Tobias Weiss; Michael Weller; Patrick Roth
Journal: Curr Opin Neurol Date: 2015-12 Impact factor: 5.710

Review 2. Prospects of immune checkpoint modulators in the treatment of glioblastoma.

Authors: Matthias Preusser; Michael Lim; David A Hafler; David A Reardon; John H Sampson
Journal: Nat Rev Neurol Date: 2015-08-11 Impact factor: 42.937

Review 3. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

Authors: Hideho Okada; Michael Weller; Raymond Huang; Gaetano Finocchiaro; Mark R Gilbert; Wolfgang Wick; Benjamin M Ellingson; Naoya Hashimoto; Ian F Pollack; Alba A Brandes; Enrico Franceschi; Christel Herold-Mende; Lakshmi Nayak; Ashok Panigrahy; Whitney B Pope; Robert Prins; John H Sampson; Patrick Y Wen; David A Reardon
Journal: Lancet Oncol Date: 2015-11 Impact factor: 41.316

3 in total

21 in total

1. PET imaging in patients with brain metastasis-report of the RANO/PET group.

Authors: Norbert Galldiks; Karl-Josef Langen; Nathalie L Albert; Marc Chamberlain; Riccardo Soffietti; Michelle M Kim; Ian Law; Emilie Le Rhun; Susan Chang; Julian Schwarting; Stephanie E Combs; Matthias Preusser; Peter Forsyth; Whitney Pope; Michael Weller; Jörg C Tonn
Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300

Review 2. Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).

Authors: Sui Li; Xiaofang Xie; Fu Peng; Junrong Du; Cheng Peng
Journal: Int J Oncol Date: 2022-07-07 Impact factor: 5.884

3. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.

Authors: Víctor A Arrieta; Andrew X Chen; J Robert Kane; Seong Jae Kang; Cynthia Kassab; Crismita Dmello; Junfei Zhao; Kirsten B Burdett; Pavan S Upadhyayula; Catalina Lee-Chang; Joseph Shilati; Dinesh Jaishankar; Li Chen; Andrew Gould; Daniel Zhang; Jinzhou Yuan; Wenting Zhao; Xiaoyang Ling; Jared K Burks; Brice Laffleur; Christina Amidei; Jeffrey N Bruce; Rimas V Lukas; Jonathan T Yamaguchi; David Cieremans; Gerson Rothschild; Uttiya Basu; Matthew McCord; Daniel J Brat; Hui Zhang; Lee A D Cooper; Bin Zhang; Peter Sims; Tim F Cloughesy; Robert Prins; Peter Canoll; Roger Stupp; Amy B Heimberger; Craig Horbinski; Fabio M Iwamoto; Raul Rabadan; Adam M Sonabend
Journal: Nat Cancer Date: 2021-11-29

4. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial.

Authors: E Antonio Chiocca; Arnold B Gelb; Clark C Chen; Ganesh Rao; David A Reardon; Patrick Y Wen; Wenya Linda Bi; Pierpaolo Peruzzi; Christina Amidei; Dan Triggs; Leah Seften; Grace Park; James Grant; Kyla Truman; Jill Y Buck; Nira Hadar; Nathan Demars; John Miao; Taylor Estupinan; John Loewy; Kamal Chadha; Joseph Tringali; Laurence Cooper; Rimas V Lukas
Journal: Neuro Oncol Date: 2022-06-01 Impact factor: 13.029

5. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

Authors: Sara A Byron; Nhan L Tran; Rebecca F Halperin; Joanna J Phillips; John G Kuhn; John F de Groot; Howard Colman; Keith L Ligon; Patrick Y Wen; Timothy F Cloughesy; Ingo K Mellinghoff; Nicholas A Butowski; Jennie W Taylor; Jennifer L Clarke; Susan M Chang; Mitchel S Berger; Annette M Molinaro; Gerald M Maggiora; Sen Peng; Sara Nasser; Winnie S Liang; Jeffrey M Trent; Michael E Berens; John D Carpten; David W Craig; Michael D Prados
Journal: Clin Cancer Res Date: 2017-10-26 Impact factor: 12.531

Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.

Review 1. Immunotherapy for glioblastoma: concepts and challenges.

Review 2. Prospects of immune checkpoint modulators in the treatment of glioblastoma.

Review 3. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

1. PET imaging in patients with brain metastasis-report of the RANO/PET group.

Review 2. Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).

3. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.

4. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial.

5. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

6. PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.

7. Adding DSC PWI and DWI to BT-RADS can help identify postoperative recurrence in patients with high-grade gliomas.

Review 8. Emerging Applications of Artificial Intelligence in Neuro-Oncology.

9. Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.

10. Considerations when treating high-grade pediatric glioma patients with immunotherapy.